These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 23483575)

  • 1. Corticosteroids in Duchenne muscular dystrophy: major variations in practice.
    Griggs RC; Herr BE; Reha A; Elfring G; Atkinson L; Cwik V; McColl E; Tawil R; Pandya S; McDermott MP; Bushby K
    Muscle Nerve; 2013 Jul; 48(1):27-31. PubMed ID: 23483575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Corticosteroids for the treatment of Duchenne muscular dystrophy.
    Matthews E; Brassington R; Kuntzer T; Jichi F; Manzur AY
    Cochrane Database Syst Rev; 2016 May; 2016(5):CD003725. PubMed ID: 27149418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
    Manzur AY; Kuntzer T; Pike M; Swan A
    Cochrane Database Syst Rev; 2008 Jan; (1):CD003725. PubMed ID: 18254031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
    Manzur AY; Kuntzer T; Pike M; Swan A
    Cochrane Database Syst Rev; 2004; (2):CD003725. PubMed ID: 15106215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Practice guideline update summary: Corticosteroid treatment of Duchenne muscular dystrophy: Report of the Guideline Development Subcommittee of the American Academy of Neurology.
    Gloss D; Moxley RT; Ashwal S; Oskoui M
    Neurology; 2016 Feb; 86(5):465-72. PubMed ID: 26833937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Outcomes in Duchenne Muscular Dystrophy: A Study of 5345 Patients from the TREAT-NMD DMD Global Database.
    Koeks Z; Bladen CL; Salgado D; van Zwet E; Pogoryelova O; McMacken G; Monges S; Foncuberta ME; Kekou K; Kosma K; Dawkins H; Lamont L; Bellgard MI; Roy AJ; Chamova T; Guergueltcheva V; Chan S; Korngut L; Campbell C; Dai Y; Wang J; Barišić N; Brabec P; Lähdetie J; Walter MC; Schreiber-Katz O; Karcagi V; Garami M; Herczegfalvi A; Viswanathan V; Bayat F; Buccella F; Ferlini A; Kimura E; van den Bergen JC; Rodrigues M; Roxburgh R; Lusakowska A; Kostera-Pruszczyk A; Santos R; Neagu E; Artemieva S; Rasic VM; Vojinovic D; Posada M; Bloetzer C; Klein A; Díaz-Manera J; Gallardo E; Karaduman AA; Oznur T; Topaloğlu H; El Sherif R; Stringer A; Shatillo AV; Martin AS; Peay HL; Kirschner J; Flanigan KM; Straub V; Bushby K; Béroud C; Verschuuren JJ; Lochmüller H
    J Neuromuscul Dis; 2017; 4(4):293-306. PubMed ID: 29125504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study.
    Smith EC; Conklin LS; Hoffman EP; Clemens PR; Mah JK; Finkel RS; Guglieri M; Tulinius M; Nevo Y; Ryan MM; Webster R; Castro D; Kuntz NL; Kerchner L; Morgenroth LP; Arrieta A; Shimony M; Jaros M; Shale P; Gordish-Dressman H; Hagerty L; Dang UJ; Damsker JM; Schwartz BD; Mengle-Gaw LJ; McDonald CM;
    PLoS Med; 2020 Sep; 17(9):e1003222. PubMed ID: 32956407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Different Corticosteroid Dosing Regimens on Clinical Outcomes in Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial.
    Guglieri M; Bushby K; McDermott MP; Hart KA; Tawil R; Martens WB; Herr BE; McColl E; Speed C; Wilkinson J; Kirschner J; King WM; Eagle M; Brown MW; Willis T; Griggs RC; ; Straub V; van Ruiten H; Childs AM; Ciafaloni E; Shieh PB; Spinty S; Maggi L; Baranello G; Butterfield RJ; Horrocks IA; Roper H; Alhaswani Z; Flanigan KM; Kuntz NL; Manzur A; Darras BT; Kang PB; Morrison L; Krzesniak-Swinarska M; Mah JK; Mongini TE; Ricci F; von der Hagen M; Finkel RS; O'Reardon K; Wicklund M; Kumar A; McDonald CM; Han JJ; Joyce N; Henricson EK; Schara-Schmidt U; Gangfuss A; Wilichowski E; Barohn RJ; Statland JM; Campbell C; Vita G; Vita GL; Howard JF; Hughes I; McMillan HJ; Pegoraro E; Bello L; Burnette WB; Thangarajh M; Chang T
    JAMA; 2022 Apr; 327(15):1456-1468. PubMed ID: 35381069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variability and trends in corticosteroid use by male United States participants with Duchenne muscular dystrophy in the Duchenne Registry.
    Cowen L; Mancini M; Martin A; Lucas A; Donovan JM
    BMC Neurol; 2019 May; 19(1):84. PubMed ID: 31046703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interventions to prevent and treat corticosteroid-induced osteoporosis and prevent osteoporotic fractures in Duchenne muscular dystrophy.
    Bell JM; Shields MD; Watters J; Hamilton A; Beringer T; Elliott M; Quinlivan R; Tirupathi S; Blackwood B
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD010899. PubMed ID: 28117876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical management of muscle weakness in Duchenne muscular dystrophy.
    Rivera SR; Jhamb SK; Abdel-Hamid HZ; Acsadi G; Brandsema J; Ciafaloni E; Darras BT; Iannaccone ST; Konersman CG; Kuntz NL; McDonald CM; Parsons JA; Tesi Rocha C; Zaidman CM; Butterfield RJ; Connolly AM; Mathews KD
    PLoS One; 2020; 15(10):e0240687. PubMed ID: 33075081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disease progression rates in ambulatory Duchenne muscular dystrophy by steroid type, patient age and functional status.
    McDonald CM; Marden JR; Shieh PB; Wong BL; Lane H; Zhang A; Nguyen H; Frean M; Trifillis P; Koladicz K; Signorovitch J
    J Comp Eff Res; 2023 Apr; 12(4):e220190. PubMed ID: 36749302
    [No Abstract]   [Full Text] [Related]  

  • 13. Use of corticosteroids in a population-based cohort of boys with duchenne and becker muscular dystrophy.
    Matthews DJ; James KA; Miller LA; Pandya S; Campbell KA; Ciafaloni E; Mathews KD; Miller TM; Cunniff C; Meaney FJ; Druschel CM; Romitti PA; Fox DJ;
    J Child Neurol; 2010 Nov; 25(11):1319-24. PubMed ID: 20207610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. European Cross-Sectional Survey of Current Care Practices for Duchenne Muscular Dystrophy Reveals Regional and Age-Dependent Differences.
    Vry J; Gramsch K; Rodger S; Thompson R; Steffensen BF; Rahbek J; Doerken S; Tassoni A; Beytía ML; Guergueltcheva V; Chamova T; Tournev I; Kostera-Pruszczyk A; Kaminska A; Lusakowska A; Mrazova L; Pavlovska L; Strenkova J; Vondráček P; Garami M; Karcagi V; Herczegfalvi Á; Bushby K; Lochmüller H; Kirschner J
    J Neuromuscul Dis; 2016 Nov; 3(4):517-527. PubMed ID: 27911335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time to diagnosis of Duchenne muscular dystrophy in Austria and Germany.
    Hiebeler M; Thiele S; Reilich P; Bernert G; Walter MC
    Sci Rep; 2023 Jan; 13(1):179. PubMed ID: 36604563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Vamorolone vs Placebo and Prednisone Among Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial.
    Guglieri M; Clemens PR; Perlman SJ; Smith EC; Horrocks I; Finkel RS; Mah JK; Deconinck N; Goemans N; Haberlova J; Straub V; Mengle-Gaw LJ; Schwartz BD; Harper AD; Shieh PB; De Waele L; Castro D; Yang ML; Ryan MM; McDonald CM; Tulinius M; Webster R; McMillan HJ; Kuntz NL; Rao VK; Baranello G; Spinty S; Childs AM; Sbrocchi AM; Selby KA; Monduy M; Nevo Y; Vilchez-Padilla JJ; Nascimento-Osorio A; Niks EH; de Groot IJM; Katsalouli M; James MK; van den Anker J; Damsker JM; Ahmet A; Ward LM; Jaros M; Shale P; Dang UJ; Hoffman EP
    JAMA Neurol; 2022 Oct; 79(10):1005-1014. PubMed ID: 36036925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Review of Deflazacort for Patients With Duchenne Muscular Dystrophy.
    Bylo M; Farewell R; Coppenrath VA; Yogaratnam D
    Ann Pharmacother; 2020 Aug; 54(8):788-794. PubMed ID: 32019318
    [No Abstract]   [Full Text] [Related]  

  • 18. Deflazacort vs prednisone treatment for Duchenne muscular dystrophy: A meta-analysis of disease progression rates in recent multicenter clinical trials.
    McDonald CM; Sajeev G; Yao Z; McDonnell E; Elfring G; Souza M; Peltz SW; Darras BT; Shieh PB; Cox DA; Landry J; Signorovitch J;
    Muscle Nerve; 2020 Jan; 61(1):26-35. PubMed ID: 31599456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Developing standardized corticosteroid treatment for Duchenne muscular dystrophy.
    Guglieri M; Bushby K; McDermott MP; Hart KA; Tawil R; Martens WB; Herr BE; McColl E; Wilkinson J; Kirschner J; King WM; Eagle M; Brown MW; Willis T; Hirtz D; Shieh PB; Straub V; Childs AM; Ciafaloni E; Butterfield RJ; Horrocks I; Spinty S; Flanigan KM; Kuntz NL; Baranello G; Roper H; Morrison L; Mah JK; Manzur AY; McDonald CM; Schara U; von der Hagen M; Barohn RJ; Campbell C; Darras BT; Finkel RS; Vita G; Hughes I; Mongini T; Pegoraro E; Wicklund M; Wilichowski E; Bryan Burnette W; Howard JF; McMillan HJ; Thangarajh M; Griggs RC
    Contemp Clin Trials; 2017 Jul; 58():34-39. PubMed ID: 28450193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antioxidants to prevent respiratory decline in people with Duchenne muscular dystrophy and progressive respiratory decline.
    Garegnani L; Hyland M; Roson Rodriguez P; Escobar Liquitay CM; Franco JV
    Cochrane Database Syst Rev; 2021 Dec; 12(12):CD013720. PubMed ID: 34850383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.